Suppr超能文献

相似文献

2
Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention.
Front Immunol. 2021 Feb 26;12:632564. doi: 10.3389/fimmu.2021.632564. eCollection 2021.
3
From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
Cancer Res. 2018 May 15;78(10):2449-2456. doi: 10.1158/0008-5472.CAN-17-3115. Epub 2018 Apr 27.
4
Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Eur J Haematol. 2015 Sep;95(3):211-7. doi: 10.1111/ejh.12473. Epub 2015 Jan 7.
5
Multiple Myeloma and the Immune Microenvironment.
Curr Cancer Drug Targets. 2017;17(9):806-818. doi: 10.2174/1568009617666170214102301.
7
Mass Cytometry Discovers Two Discrete Subsets of CD39Treg Which Discriminate MGUS From Multiple Myeloma.
Front Immunol. 2019 Aug 2;10:1596. doi: 10.3389/fimmu.2019.01596. eCollection 2019.
8
Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Curr Opin Hematol. 2016 Jul;23(4):426-33. doi: 10.1097/MOH.0000000000000259.
9
Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects.
Curr Hematol Malig Rep. 2020 Apr;15(2):45-55. doi: 10.1007/s11899-020-00569-2.
10
Treg and Oligoclonal Expansion of Terminal Effector CD8 T Cell as Key Players in Multiple Myeloma.
Front Immunol. 2021 Feb 23;12:620596. doi: 10.3389/fimmu.2021.620596. eCollection 2021.

引用本文的文献

1
Exploring multiple myeloma pathobiology and immune cell signatures: Evidence from bidirectional genetic analysis.
Medicine (Baltimore). 2025 Sep 5;104(36):e44276. doi: 10.1097/MD.0000000000044276.
2
CyTOF profiling of bone marrow immune dynamics across myeloma stages.
Oncoimmunology. 2025 Dec;14(1):2542333. doi: 10.1080/2162402X.2025.2542333. Epub 2025 Aug 18.
3
Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies.
Cancers (Basel). 2025 Jul 10;17(14):2292. doi: 10.3390/cancers17142292.
4
Altered dynamics of T cell subsets in peripheral blood impacts disease progression in newly diagnosed multiple myeloma.
Biochem Biophys Rep. 2025 Jun 23;43:102104. doi: 10.1016/j.bbrep.2025.102104. eCollection 2025 Sep.
5
T cell phenotype and clonality changes in myeloma patients with short overall survival.
JCI Insight. 2025 Apr 22;10(11). doi: 10.1172/jci.insight.181096. eCollection 2025 Jun 9.
8
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma.
Blood Adv. 2025 May 27;9(10):2438-2442. doi: 10.1182/bloodadvances.2024015680.
9
Immunocompetent mouse models of multiple myeloma.
Semin Hematol. 2025 Feb;62(1):50-57. doi: 10.1053/j.seminhematol.2024.11.003. Epub 2024 Nov 16.
10
Smoldering multiple myeloma: Integrating biology and risk into management.
Semin Hematol. 2025 Feb;62(1):3-10. doi: 10.1053/j.seminhematol.2024.10.002. Epub 2024 Oct 18.

本文引用的文献

1
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038.
3
High-dimensional single cell analysis identifies stem-like cytotoxic CD8 T cells infiltrating human tumors.
J Exp Med. 2018 Oct 1;215(10):2520-2535. doi: 10.1084/jem.20180684. Epub 2018 Aug 28.
4
Role of Tissue-Resident Memory in Intra-Tumor Heterogeneity and Response to Immune Checkpoint Blockade.
Front Immunol. 2018 Jul 16;9:1655. doi: 10.3389/fimmu.2018.01655. eCollection 2018.
5
TCF1 expression marks self-renewing human CD8 T cells.
Blood Adv. 2018 Jul 24;2(14):1685-1690. doi: 10.1182/bloodadvances.2018016279.
6
Tissue-resident memory T cells at the center of immunity to solid tumors.
Nat Immunol. 2018 Jun;19(6):538-546. doi: 10.1038/s41590-018-0114-2. Epub 2018 May 18.
7
Transcriptional programming of tissue-resident memory CD8 T cells.
Curr Opin Immunol. 2018 Apr;51:162-169. doi: 10.1016/j.coi.2018.03.017. Epub 2018 Apr 2.
8
CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions.
Annu Rev Med. 2018 Jan 29;69:301-318. doi: 10.1146/annurev-med-012017-043208.
9
Local proliferation maintains a stable pool of tissue-resident memory T cells after antiviral recall responses.
Nat Immunol. 2018 Feb;19(2):183-191. doi: 10.1038/s41590-017-0027-5. Epub 2018 Jan 8.
10
Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy.
Blood Adv. 2017 Nov 20;1(25):2343-2347. doi: 10.1182/bloodadvances.2017012732. eCollection 2017 Nov 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验